

KFIN/CERT13(3)/JUN/2025

Date : July 17, 2025

Mr. Ajay Nadkarni
M/s. GlaxoSmithKline Pharmaceuticals Limited
Dr. Annie Besant Road
Worli, Mumbai-400025.

Sub : Investor Grievance Certificate for the quarter ended June 30, 2025.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended June 30, 2025.

Description of Complaint	Opening Balance as on 01.04.2025	Received during the Period 01.04.2025 to 30.06.2025	Attended/Resolved during the Period 01.04.2025 to 30.06.2025	Pending as on 30.06.2025
Non-receipt of Dividend	NIL	NIL	NIL	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of shares	NIL	NIL	NIL	NIL
SEBI	01	08	05	04
Stock Exchange	NIL	NIL	NIL	NIL
ODR	NIL	2	2	NIL
Total	01	10	07	04

This is for your information and record.

Thanking you,

Yours faithfully
For KFin Technologies Limited



Dnyanesh Gharote
Vice President

KFin Technologies Limited **Operations Centre:**

KFin Technologies Limited, Selenium, Tower B, Plot No-31 & 32,
Financial District, Nanakramguda, Serilingampally,
Hyderabad - 500032, Telangana, India.

Registered Office:

KFin Technologies Limited, 301, The Centrium,
3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada,
Kurla (West), Mumbai - 400 070, Maharashtra

CIN: L72400MH2017PLC444072